Journal
BLOOD
Volume 109, Issue 3, Pages 862-867Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2006-07-028829
Keywords
-
Categories
Funding
- NCI NIH HHS [CA102 583, CA078 606] Funding Source: Medline
- NHLBI NIH HHS [R01HL082 981] Funding Source: Medline
Ask authors/readers for more resources
Elucidation of the molecular mechanisms underlying carcinogenesis has benefited tremendously from the identification and characterization of oncogenes and tumor suppressor genes. One new advance in this field is the identification of PTPN11 as the first proto-oncogene that encodes a cytoplasmic tyrosine phosphatase with 2 Src-homology 2 (SH2) domains (Shp2). This tyrosine phosphatase was previously shown to play an essential role in normal hematopoiesis. More recently, somatic missense PTPN11 gain-of-function mutations have been detected in leukemias and rarely in solid tumors, and have been found to induce aberrant hyperactivation of the Ras-Erk pathway. This progress represents another milestone in the leukemia/cancer research field and provides a fresh view on the molecular mechanisms underlying cell transformation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available